Currently Viewing:
Currently Reading
Polypharmacy Plays a Role in Patients With Relapsing-Remitting Multiple Sclerosis
February 17, 2019 – Laura Joszt
Review Find Moderate Evidence That Aerobic Exercise Lowers Number of Migraine Days
February 16, 2019 – Jaime Rosenberg
Continuous Fingolimod Treatment Leads to 50% Reduction of ARRs
February 15, 2019 – Samantha DiGrande
CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy
February 15, 2019 – Mary Caffrey and Allison Inserro
What We're Reading: Syphilis Rates Rising; House Democrats and ACA Suit; WHO to Look at Gene Editing
February 15, 2019 – AJMC Staff
HCCI Report: Healthcare Spending Increased Even as Utilization Decreased or Stagnated
February 15, 2019 – Wallace Stephens
AJMC® in the Press, February 15, 2019
February 15, 2019 – AJMC Staff
5 Findings From the February 2019 Issue of AJMC®
February 15, 2019 – Christina Mattina
This Week in Managed Care: February 15, 2019
February 15, 2019

Insurance Guidelines Lead to Greater Out-of-Pocket Costs for Patients With MS

Samantha DiGrande
A study recently published in Health Affairs found that Medicare beneficiaries without low-income subsidies will pay more than $6000 a year out-of-pocket on multiple sclerosis (MS) drugs alone.
The high cost of multiple sclerosis (MS) therapies has created an access problem for patients who can’t afford the medications due to high out-of-pocket costs.

A study recently published in Health Affairs found that Medicare beneficiaries without low-income subsidies will pay more than $6000 a year out-of-pocket on MS drugs alone. The study authors looked to describe changes in pharmacy benefit coverage and cost-sharing amounts for MS therapies in the Medicare Part D program by analyzing enrollment-weighted Prescription Drug Plan Formulary filed from 2007 to 2016.

Interestingly, the study found that for patients who were prescribed the only generic medication in 1 drug class, glatiramer acetate, paid more out-of-pocket than patients using any of the other brand name drugs in the same class.

The authors explained that while the Bipartisan Budget Act of 2018 adapted Medicare payment guidelines to reduce out-of-pocket costs for patients through increased discounts offered by brand name manufacturers, it left patients who use generics with higher out-of-pocket costs for certain generic products.

“This is a pernicious effect of the release of a generic and an unfortunate effect of Medicare rules,” study coauthor Dennis Bourdette, MD, professor and chair of neurology in the Oregon Health & Science University School of Medicine, said in a statement.

Additionally, the authors found that throughout the period studied, the rate of prior authorization increased from 61% to 66% across included plans to 84% to 90%. Prior authorization, used a strategy to manage access to certain expensive drugs or procedures, can delay treatment for patients. Although there has been an increase in MS treatment options, the out-of-pocket costs incurred by patients has continued to increase.

“It’s a dysfunctional market that lacks the typical incentives for most other consumer prices,” commented lead author Daniel Hartung, PharmD, MPH.

The study authors concluded that when writing policy, lawmakers should consider both access restrictions and a growing cost-sharing burden as potential consequences of high and rising drug prices for patients with MS.


Hartun D, Johnston K, Irwin A, Markwardt S, Bourdette D. Trends in coverage for disease-modifying therapies for multiple sclerosis in Medicare Part D. Health Affairs. 2019;28(2).

Related Articles

Researchers Identify New Therapeutic Approach to Multiple Sclerosis With Sephin1
HHS Proposes to End Drug Rebates in Medicare, Medicaid Managed Care
Fingolimod Significantly Reduces Relapse in MS Compared With Dimethyl Fumarate, Teriflunomide
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!